Particularly, Canakinumab, a fully human monoclonal antibody against IL-1β, in combination with Pembrolizumab anti-PD-1 antibody delayed tumor growth and increased infiltration of CD8 T cells in a humanized bone marrow liver thymic non-small cell lung cancer model [29]. Here, CD8A is linked to neoplasm.